<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00488813</url>
  </required_header>
  <id_info>
    <org_study_id>101441</org_study_id>
    <nct_id>NCT00488813</nct_id>
  </id_info>
  <brief_title>Study of Antibiotic Utilization Measures and Control of ESBLs in China</brief_title>
  <official_title>Association of Antibiotic Utilization Measures and Control of Extended-spectrum β-lactamases (ESBLs) in MICU1 and MICU2 at Buddhist Tzu Chi General Hospital.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wyeth is now a wholly owned subsidiary of Pfizer</source>
  <brief_summary>
    <textblock>
      A single-center, prospective, comparative, antibiotic intervention study for patients
      admitted to MICU1 and MICU2
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. To determine the value of using β-lactamases inhibitors in reducing the cases of ESBL
           producing E. coli or K. pneumoniae colonization and infection after 12 months.

        2. To compare the acquisition rates of ESBL producing E. coli or K. pneumoniae at MICU1 and
           MICU2 after 12 months
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">June 2005</completion_date>
  <primary_completion_date type="Actual">June 2005</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>For both MICU1 and MICU2 (acquisition), all culture results will be collected and recorded, then analyzed to determine the ESBL acquisition rate and bacterial isolates (E. coli or K. pneumoniae).</measure>
  </primary_outcome>
  <enrollment>300</enrollment>
  <condition>ICU Patient</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Third generation cephalosporins</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients admitted or transferred to the ICU/burn units.

          -  Patients of either sex, 18 years of age or older.

        Exclusion Criteria:

          -  Patient with hypersensitivity to penicillins, cephalosporins, and beta-lactamase
             inhibitors.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Wyeth is now a wholly owned subsidiary of Pfizer</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Trial Manager</last_name>
    <role>Principal Investigator</role>
    <affiliation>For Taiwan, medinfo@wyeth.com</affiliation>
  </overall_official>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 18, 2007</study_first_submitted>
  <study_first_submitted_qc>June 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2007</study_first_posted>
  <last_update_submitted>September 4, 2009</last_update_submitted>
  <last_update_submitted_qc>September 4, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2009</last_update_posted>
  <keyword>Tzh-Chi ESBL study</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Cephalosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

